Christian C Felder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10799891/publications.pdf

Version: 2024-02-01

77 papers	7,751 citations	81900 39 h-index	76900 74 g-index
80 all docs	80 docs citations	80 times ranked	6619 citing authors

#	Article	IF	Citations
1	Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature, 2013, 504, 101-106.	27.8	779
2	Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a G_sLinkage to the CB1 Receptor. Journal of Neuroscience, 1997, 17, 5327-5333.	3.6	565
3	Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1020-1024.	2.5	531
4	Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB Journal, 1995, 9, 619-625.	0.5	468
5	Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. American Journal of Psychiatry, 2008, 165, 1033-1039.	7.2	430
6	Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature, 2001, 410, 207-212.	27.8	349
7	CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS. Annual Review of Pharmacology and Toxicology, 1998, 38, 179-200.	9.4	348
8	Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters, 1996, 393, 231-235.	2.8	295
9	Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature, 2016, 531, 335-340.	27.8	272
10	Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology Biochemistry and Behavior, 1993, 46, 967-972.	2.9	222
11	The endocannabinoid nervous system. , 2001, 90, 45-60.		218
12	Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System. Journal of Medicinal Chemistry, 2000, 43, 4333-4353.	6.4	209
13	Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochemical Research, 2003, 28, 437-442.	3.3	177
14	Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses,in vivophosphoinositide hydrolysis, and pilocarpine-induced seizure activity. European Journal of Neuroscience, 2003, 17, 1403-1410.	2.6	153
15	Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties. Neuropsychopharmacology, 2010, 35, 855-869.	5.4	143
16	Evaluation of Muscarinic Agonist-Induced Analgesia in Muscarinic Acetylcholine Receptor Knockout Mice. Molecular Pharmacology, 2002, 62, 1084-1093.	2.3	133
17	Muscarinic mechanisms of antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1125-1143.	4.8	123
18	Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. Cerebral Cortex, 2016, 26, 414-426.	2.9	120

#	Article	IF	Citations
19	Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects. Molecular Pharmacology, 2012, 81, 41-52.	2.3	115
20	Elucidating the role of muscarinic receptors in psychosis. Life Sciences, 2001, 68, 2605-2613.	4.3	106
21	New Insights into the Function of M₄ Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer) Tj ETQq1 1 0.784314 rgBT /Overlock	4.3	103
22	Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice. Life Sciences, 2003, 72, 2047-2054.	4.3	93
23	Imaging and Quantitation of Cannabinoid CB₁ Receptors in Human and Monkey Brains Using ¹⁸F-Labeled Inverse Agonist Radioligands. Journal of Nuclear Medicine, 2010, 51, 112-120.	5.0	91
24	Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. NeuroImage, 2009, 48, 362-370.	4.2	86
25	M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Research, 2002, 944, 82-89.	2.2	84
26	The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain. Neuropsychopharmacology, 2008, 33, 259-269.	5.4	80
27	Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2010, 285, 19012-19021.	3.4	70
28	Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Subtype-1 Receptor Ligands as Candidates for In Vivo Imaging. Journal of Medicinal Chemistry, 2008, 51, 5833-5842.	6.4	69
29	Cannabinoid receptors and their endogenous agonist, anandamide. Neurochemical Research, 1998, 23, 575-581.	3.3	65
30	Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology, 2018, 136, 449-458.	4.1	65
31	Rapid High-Energy Microwave Fixation is Required to Determine the Anandamide (N-arachidonoylethanolamine) Concentration of Rat Brain. Neurochemical Research, 2005, 30, 597-601.	3.3	64
32	Cloning and characterization of the rat 5-HT5B receptor. FEBS Letters, 1993, 333, 25-31.	2.8	60
33	Voltage-independent calcium channels. Biochemical Pharmacology, 1994, 48, 1997-2004.	4.4	59
34	Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Life Sciences, 2001, 68, 2457-2466.	4.3	56
35	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. Journal of Clinical Investigation, 2016, 127, 487-499.	8.2	56
36	?1-Adrenergic Receptor Mediates Arachidonic Acid Release in Spinal Cord Neurons Independent of Inositol Phospholipid Turnover. Journal of Neurochemistry, 1990, 54, 1225-1232.	3.9	51

#	Article	IF	Citations
37	Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. NeuroImage, 2008, 41, 690-698.	4.2	47
38	Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature Communications, 2019, 10, 3289.	12.8	47
39	Pharmacological Characterization of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Inhibitors. Cellular and Molecular Neurobiology, 2006, 26, 405-421.	3.3	46
40	The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biological Psychiatry, 2001, 49, 716-725.	1.3	43
41	Cannabinoids Biology: The Search for New Therapeutic Targets. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 149-161.	3.4	42
42	Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M₂and M₄Receptors. Molecular Pharmacology, 2014, 86, 106-115.	2.3	42
43	GABA_A Receptors Modulate Early Spontaneous Excitatory Activity in Differentiating P19 Neurons. Journal of Neurochemistry, 1996, 66, 233-242.	3.9	39
44	An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory. Journal of Biological Chemistry, 2016, 291, 8862-8875.	3.4	34
45	The Role of Transmembrane Domain 3 in the Actions of Orthosteric, Allosteric, and Atypical Agonists of the M₄Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2011, 79, 855-865.	2.3	32
46	Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. Journal of Chemical Neuroanatomy, 2010, 40, 63-70.	2.1	31
47	Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 622-632.	2.5	31
48	The Signal Transducer for the Dopamine-1 Regulated Sodium Transport in Renal Cortical Brush Border Membrane Vesicles. American Journal of Hypertension, 1990, 3, 47S-50S.	2.0	30
49	Identification and Molecular Characterization of a m5 Muscarinic Receptor in A2058 Human Melanoma Cells. Journal of Biological Chemistry, 1996, 271, 17476-17484.	3.4	30
50	Receptor-coupled Amyloid Precursor Protein Processinga. Annals of the New York Academy of Sciences, 1993, 695, 122-127.	3.8	29
51	Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. American Journal of Psychiatry, 2022, 179, 611-627.	7.2	29
52	Muscarinic receptors mediate the release of arachidonic acid from spinal cord and hippocampal neurons in primary culture. Neuroscience Letters, 1990, 118, 235-237.	2.1	27
53	Development of a Radioligand, [3H]LY2119620, to Probe the Human M2 and M4 Muscarinic Receptor Allosteric Binding Sites. Molecular Pharmacology, 2014, 86, 116-123.	2.3	25
54	Bitopic Binding Mode of an M₁ Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology, 2018, 93, 645-656.	2.3	25

#	Article	IF	Citations
55	Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1499-1506.	6.4	22
56	¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁ In Vivo. Journal of Nuclear Medicine, 2015, 56, 317-322.	5.0	22
57	Characterization of PCS1055, a novel muscarinic M4 receptor antagonist. European Journal of Pharmacology, 2016, 782, 70-76.	3.5	20
58	Muscarinic Acetylcholine Receptor Subtypes Associated with Release of Alzheimer Amyloid Precursor Derivatives Activate Multiple Signal Transduction Pathways. Annals of the New York Academy of Sciences, 1993, 695, 15-18.	3.8	14
59	GPCR drug discovery-moving beyond the orthosteric to the allosteric domain. Advances in Pharmacology, 2019, 86, 1-20.	2.0	14
60	The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype. Neuropsychopharmacology, 2013, 38, 2717-2726.	5.4	13
61	Carbachol-induced reverse transformation of Chinese hamster ovary cells transfected with and expressing the m5 muscarinic acetylcholine receptor. FEBS Letters, 1989, 245, 75-79.	2.8	10
62	The third intracellular domain of the m3 muscarinic receptor determines coupling to calcium influx in transfected Chinese hamster ovary cells. FEBS Letters, 1996, 386, 51-54.	2.8	10
63	Inflammatory Cytokines Enhance Muscarinic-Mediated Arachidonic Acid Release Through p38 Mitogen-Activated Protein Kinase in A2058 Cells. Journal of Neurochemistry, 2008, 74, 2033-2040.	3.9	10
64	Translational Pharmacology of the Metabotropic Glutamate 2 Receptorâ€“Preferring Agonist LY2812223 in the Animal and Human Brain. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 190-197.	2.5	10
65	In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 602-613.	2.5	10
66	Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo. Brain Research, 2001, 916, 165-171.	2.2	9
67	Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M₁ receptors. British Journal of Pharmacology, 2019, 176, 110-126.	5.4	9
68	Independent induction of morphological transformation of CHO cells by receptor-activated cyclic AMP synthesis or by receptor-operated calcium influx. Biochemical Pharmacology, 1996, 51, 495-502.	4.4	7
69	Pharmacological characterization of the cannabinoid CB1 receptor PET ligand ortholog, [3H]MePPEP. European Journal of Pharmacology, 2010, 649, 44-50.	3.5	6
70	Biased Profile of Xanomeline at the Recombinant Human M₄ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2022, 13, 1206-1218.	3.5	6
71	Drs. Shekhar, McKinzie, and Felder Reply. American Journal of Psychiatry, 2009, 166, 113-113.	7.2	5
72	Chapter 18 Muscarinic receptor activated Ca2+channels in non-excitable cells. Progress in Brain Research, 1996, 109, 195-199.	1.4	4

#	Article	IF	Citations
73	Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4158-4163.	2.2	4
74	Antipsychotic-Like Effect of the Muscarinic Acetylcholine Receptor Agonist BuTAC in Non-Human Primates. PLoS ONE, 2015, 10, e0122722.	2.5	2
75	Endocannabinoids and their receptors as targets for treating metabolic and psychiatric disorders. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 561-567.	0.5	1
76	The Role of Anandamide and Related Fatty Acid Ethanolamides as Endogenous Ligands for the CB1 and CB2 Cannabinoid Receptors. , 1996, , 157-164.		1
77	Identification, expression and functional characterization of M4L, a muscarinic acetylcholine M4 receptor splice variant. PLoS ONE, 2017, 12, e0188330.	2.5	0